Thurston Springer Miller Herd & Titak’s Novavax NVAX Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$188	Hold	20	–	–	﹤0.01%	1221
2026 Q1	$162	Hold	20	–	–	﹤0.01%	1308
2025 Q4	$134	Buy	+20	New	+$151	﹤0.01%	1350
2025 Q3	–	Sell	-20	Closed	-$126	–	1094
2025 Q2	$126	Hold	20	–	–	﹤0.01%	1616
2025 Q1	$128	Hold	20	–	–	﹤0.01%	1650
2024 Q4	$160	Hold	20	–	–	﹤0.01%	1309
2024 Q3	$252	Hold	20	–	–	﹤0.01%	1499
2024 Q2	$253	Buy	+20	New	+$201	﹤0.01%	1480

Other funds holding NVAX

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

IFG

Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's NVAX Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak held its Novavax (NVAX) position steady in Q2 2026 at 20 shares worth $188. The position accounts for ﹤0.01% of the portfolio, ranked #1221.

Thurston Springer Miller Herd & Titak first reported a position in NVAX in Q2 2024 and has held it in 8 quarters since. The position peaked at $253 in Q2 2024. 52 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Thurston Springer Miller Herd & Titak held 20 shares of Novavax worth $188 as of Q2 2026.
Thurston Springer Miller Herd & Titak left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #1221 holding.
Thurston Springer Miller Herd & Titak first reported a position in Novavax in Q2 2024 and has held it in 8 quarters since.
Thurston Springer Miller Herd & Titak's Novavax position peaked at $253 in Q2 2024.
52 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.